S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Franklin Genomic Advancements ETF Stock Forecast, Price & News

-1.04 (-2.15%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
4,116 shs
Average Volume
5,997 shs
Market Capitalization
$4.73 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HELX News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Franklin Templeton Investments
Fund NameFranklin Genomic Advancements ETF
Tax ClassificationRegulated Investment Company
Inception Date2/25/2020
Fund ManagerMatthew J.Moberg, Joyce Lin

Fund Focus

Asset ClassEquity
Development LevelBlended Development

Fund Statistics

Assets Under Management$27.74 million
Average Daily Volume$0.00

ETF Expenses

Management Fee0.50%
Other Expenses0.27%
Total Expenses0.77%
Fee Waiver-0.27%
Net Expenses0.55%

Administrator, Advisor and Custodian

AdministratorFranklin Templeton Services, LLC
AdvisorFranklin Advisers, Inc.
CustodianState Street Bank and Trust Company
DistributorFranklin Templeton Distributors, Inc.
Transfer AgentState Street Bank and Trust Company
Lead Market Maker

Geographic Exposure of HELX

Currency Exposure of HELX

Sector Exposure of HELX

Industry Exposure of HELX

Franklin Genomic Advancements ETF (NYSEARCA:HELX) Frequently Asked Questions

How has Franklin Genomic Advancements ETF's stock been impacted by COVID-19 (Coronavirus)?

Franklin Genomic Advancements ETF's stock was trading at $23.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HELX shares have increased by 104.2% and is now trading at $47.3237.
View which stocks have been most impacted by COVID-19

Is Franklin Genomic Advancements ETF a good dividend stock?

Franklin Genomic Advancements ETF pays an annual dividend of $0.05 per share and currently has a dividend yield of 0.10%.

What other stocks do shareholders of Franklin Genomic Advancements ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Franklin Genomic Advancements ETF investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE).

What is Franklin Genomic Advancements ETF's stock symbol?

Franklin Genomic Advancements ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "HELX."

Who are Franklin Genomic Advancements ETF's major shareholders?

Franklin Genomic Advancements ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (89.04%), Commonwealth Equity Services LLC (15.13%), Cambridge Investment Research Advisors Inc. (8.86%), Flow Traders U.S. LLC (6.49%), Benjamin F. Edwards & Company Inc. (3.56%) and Spire Wealth Management (0.90%).

Which institutional investors are selling Franklin Genomic Advancements ETF stock?

HELX stock was sold by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Spire Wealth Management, Benjamin F. Edwards & Company Inc., and Flow Traders U.S. LLC.

Which institutional investors are buying Franklin Genomic Advancements ETF stock?

HELX stock was acquired by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., and Cambridge Investment Research Advisors Inc..

How do I buy shares of Franklin Genomic Advancements ETF?

Shares of HELX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Franklin Genomic Advancements ETF's stock price today?

One share of HELX stock can currently be purchased for approximately $47.32.

How much money does Franklin Genomic Advancements ETF make?

Franklin Genomic Advancements ETF has a market capitalization of $4.73 million.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.